BiotechTV

???????? ??????????: The CEO of Bridge Biotherapeutics, Inc. discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring. CEO James Jungkue Lee, a founder of multiple biotech companies, describes the operational experience that he suggests is a key differentiator for the company. He then walks us through two lead programs - an autotaxin inhibitor for IFP and a pellino1 inhibitor for inflammatory conditions. Full video: https://lnkd.in/gp_H8-2T BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

???????? ??????????: D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines. Founder and CEO Seulki Lee describes his training in science, part of which was working on GLP-1s years ago, and the founding of the company. He walks us through D&D's pipeline, including oral GLP medicines that have been licensed to Metsera in the United States for development. Full video: https://lnkd.in/ghpdw3zZ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

??????????????'?? ??????????????: Doug Biehn, CEO of Octave, sits down with Judy Khan Shaw for an NYSE Floor Talk. He describes Octave's diagnostic solution for MS, the first and only multivariate biomarker blood test that provides accurate measurement of MS disease activity. Plus, additional work the company is doing on Parkinson's disease. Learn more: https://www.octavebio.com/

?????????????? ????????: BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans. He describes the label and what he believes it means for the therapy's competitive position. Plus, the commercial plans that have put into place, and three key trial readouts to watch over the next year. Full video: https://lnkd.in/gqtdJYBP BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

???????? ??????????: Led by a longtime leader of Korea's biotech sector, GI INNOVATION has science-forward programs such as fusion proteins that aim to redefine IL-2 and an IgE trap that could go up against Xolair. BG Rhee walks us through GI Innovation's programs and describes what he would like to see improve about Korea's biotech sector, including an idea to create BIO Asia. Full video: https://lnkd.in/gK_fUjXY BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

???????? ???????????????????? ??????????????:?HSBC and LINUS have published the Health 2035 report on the future of healthcare based on a survey that includes responses from more than 1,000 physicians aged 21 to 35. HSBC Innovation Banking's Head of Life Science and Healthcare Katherine Andersen shares key findings, including: - Administrative burden (45%) and physician reimbursement (39%) are ranked as top barriers in delivering quality healthcare. - Artificial Intelligence will play a pivotal role in diagnoses (32%) and therapeutic decisions (31%), whereas AI is expected to impact only 8% of patient interactions, reinforcing the importance of human touch. - Preventative care, early diagnosis and addressing health inequalities are the most important variables contributing to the delivery of care. Download the full report here to see more important insights:?https://lnkd.in/ggqMVkCH Please reach out to Katherine and her team to learn how HSBC can partner with your company on your long-term goals. #sponsored

?????????????? ????????: Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies. V.P. of R&D Tim Culp describes the rationale for in vivo CAR programs, what the company will be watching for from a safety standpoint, the development path ahead, and competition. Full video: https://lnkd.in/gGiq-wRs BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

???????? ??????????: With an experienced researcher at the helm, Theragen Bio aims to leverage its sequencing and bioinformatics expertise to also develop cancer therapies. CEO Soonmyung Paik, who was a developer Oncotype Dx and the founding director of Samsung Cancer Research Institute, discusses Theragen's sequencing and bioinformatics business and how he hopes to develop cancer vaccines and targeted therapies such as against MAPK3. Full video: https://lnkd.in/gCheDNWR BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

???????????? ???????????????????? ????????: Arbutus Biopharma Corporation's CEO (interim) Michael McElhaugh summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting. He describes how 25% of patients overall, and 50% of patients who had low baseline levels of hepatitis B surface antigen, saw a functional cure. Given this learning, he also discusses the potential development plan going forward. #TLM24 Full video: https://lnkd.in/g8r35dDc BiotechTV is brough to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Klein Hersh

???????????? ???????????????????? ????????: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections. CEO Francesco Maria Lavino describes the unmet need in this area and the science behind how F2G combats it. Plus, learnings from an FDA CRL the current development and regulatory plan. Full video: https://lnkd.in/gS2jjjF9 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh